Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFOL-01: Phase 1/2 Study of Rina-S in Advanced Solid Tumors
jRCT2051250094Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of rinatabart sesutecan in endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer and 3 more (4 arms), sponsored by Genmab. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] - Part B, Objective Response Rate (ORR) by BICR per RECIST v1.1 - Part F and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2051250094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250094.